About Dong-A ST
Dong-A ST is a company based in Seoul (South Korea) founded in 1932. The company has 1,700 employees. Dong-A ST operates in a competitive market with competitors including Inflammatix, MeMed, GenMark Diagnostics, Molbio Diagnostics and Sunbird Bio, among others.
- Headquarter Seoul, South Korea
- Employees 1,700
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website donga-st.com
- Legal Name Dong-A St Co., Ltd.
- Annual Revenue$560.02 M (USD)15.89as on Dec 31, 2025
- Net Profit-$19.8 M (USD)-2237.79as on Dec 31, 2025
- EBITDA$23.16 M (USD)707.97as on Dec 31, 2025
- Employee Count1,700
IPO & Listings of Dong-A ST
Dong-A ST is a publicly listed company on the KRX with ticker symbol 170900 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Apr 2013
- Listed onKRX: 170900
- Listed entityDong-A ST Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7170900005
- Share price34,950.00 KRW (-1.27% on the day) · 2026-10-08
- Market capitalisation333,207,747,602.00 KRW
- Price to earnings40.8
- EPS (diluted, trailing year)857.35 KRW
- Dividend yield1.91%
- Volume (last session)3,730
Financials of Dong-A ST
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 808.78B KRW | -28.59B KRW | 33.45B KRW |
| 2024 | 697.87B KRW | -1.22B KRW | 4.14B KRW |
| 2023 | 663.98B KRW | 11.12B KRW | 37.52B KRW |
| 2022 | 635.39B KRW | 13.55B KRW | 38.02B KRW |
| 2021 | 593.23B KRW | 12.82B KRW | 35.51B KRW |
Detailed financial statements for Dong-A ST
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Dong-A ST
Dong-A ST operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MeMed, GenMark Diagnostics, Molbio Diagnostics and Sunbird Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| molbiodiagnostics.com | 2000 | Salcete, India | $123.98M | 714 | Point-of-care molecular platforms for infectious disease detection are developed. | |
| sunbirdbio.com | 2020 | Singapore | $14M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | – | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. | |
| curetis.com | 2007 | Holzgerlingen, Germany | $127.14M | 55 | Molecular diagnostics platform is provided for infectious disease detection. |
Detailed competitors of Dong-A ST
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dong-A ST
The website of Dong-A ST (donga-st.com) receives about 27.5K visits a month and ranks #1,082,072 among all websites worldwide, #1,342 in Biotechnology and Pharmaceuticals.
- Monthly visits27.5K
▲ 31.9% vs previous month
- Unique visitors8.9K
per month
- Global rank#1,082,072
among all websites
- Category rank#1,342
Health · Biotechnology and Pharmaceuticals
- Bounce rate28%
- Pages per visit3.0
- Average visit42 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Dong-A ST. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dailypharm.com | dailypharm.com | 100% | – | #33,384 | – |
doctorw.co.kr | doctorw.co.kr | 97% | – | #1,484,954 | – |
| medisobizanews.com | 79% | – | #283,693 | View details | |
kimsonline.co.kr | kimsonline.co.kr | 78% | – | #214,400 | – |
| healthinnews.co.kr | 74% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Dong-A ST
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Dong-A St
Complete news archive for Dong-A ST
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Dong-A ST
10 companies that operate in the same segment as Dong-A ST (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dong-A ST
Dong-A ST was founded in 1932.
Dong-A ST is headquartered in Seoul, South Korea.
Dong-A ST has 1,700 employees.
Annual revenue of Dong-A ST is $560.02M as on Dec 31, 2025.
Dong-A ST was founded in 1932 in Seoul, South Korea, and operates within the pharmaceutical sector. Generic drugs are produced, encompassing chemotherapies, recombinant erythropoietin, and anti-diabetic treatments. Medical devices such as implants and cardiac circuits are manufactured, alongside rapid diagnostic tests for infectious diseases. The companys activities span pharmaceuticals, devices, and diagnostics in the South Korean market.
Dong-A ST's top competitors include Visby Medical, Inflammatix and MeMed.
Yes, Dong-A ST is publicly traded on KRX under the ticker symbol 170900.